{"title":"有效根除铜绿假单胞菌在囊性纤维化：多中心研究。","authors":"Aynur Guliyeva, Cansu Yilmaz Yegit, Muruvvet Yanaz, Mine Kalyoncu, Merve Selçuk Balcı, Seyda Karabulut, Almala Pınar Ergenekon, Gamze Tastan, Burcu Uzunoglu, Hüseyin Arslan, Hakan Yazan, Gülay Bas Bilgin, Ebru Köstereli, Ayse Ayzıt Kılınc Sakallı, Erkan Cakır, Saniye Girit, Zeynep Seda Uyan, Yasemin Gokdemir, Ela Erdem Eralp, Fazilet Karakoc, Bulent Karadag","doi":"10.1177/00099228251351699","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pseudomonas aeruginosa (PA) eradication is crucial in cystic fibrosis (CF) management. At our center, the success rate was 21.6%, prompting a revised eradication protocol to evaluate a new regimen.</p><p><strong>Methods: </strong>Cystic fibrosis patients with first-time PA detection were included. Nonmucoid PA cases received oral ciprofloxacin (3 weeks) and inhaled tobramycin (1 month). For mucoid PA or failed eradication, ciprofloxacin (3 weeks) and extended nebulized therapy (3 months, alternating tobramycin/colistin) were used. Intravenous antibiotics were given to unwell patients.</p><p><strong>Results: </strong>Among 109 CF patients (median age: 6 years), 79 (72.5%) achieved successful eradication. Oral ciprofloxacin and tobramycin inhalation were used in 66 patients (60.6%), extended nebulized therapy in 26 (23.8%), and intravenous antibiotics in 17(15.6%).</p><p><strong>Conclusion: </strong>The revised protocol achieved a high PA eradication rate in CF patients. Adapting treatment regimens based on PA characteristics and patient condition can optimize outcomes and improve CF management.</p>","PeriodicalId":10363,"journal":{"name":"Clinical Pediatrics","volume":" ","pages":"1581-1588"},"PeriodicalIF":0.7000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effective <i>Pseudomonas aeruginosa</i> Eradication in Cystic Fibrosis: Multicenter Study.\",\"authors\":\"Aynur Guliyeva, Cansu Yilmaz Yegit, Muruvvet Yanaz, Mine Kalyoncu, Merve Selçuk Balcı, Seyda Karabulut, Almala Pınar Ergenekon, Gamze Tastan, Burcu Uzunoglu, Hüseyin Arslan, Hakan Yazan, Gülay Bas Bilgin, Ebru Köstereli, Ayse Ayzıt Kılınc Sakallı, Erkan Cakır, Saniye Girit, Zeynep Seda Uyan, Yasemin Gokdemir, Ela Erdem Eralp, Fazilet Karakoc, Bulent Karadag\",\"doi\":\"10.1177/00099228251351699\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pseudomonas aeruginosa (PA) eradication is crucial in cystic fibrosis (CF) management. At our center, the success rate was 21.6%, prompting a revised eradication protocol to evaluate a new regimen.</p><p><strong>Methods: </strong>Cystic fibrosis patients with first-time PA detection were included. Nonmucoid PA cases received oral ciprofloxacin (3 weeks) and inhaled tobramycin (1 month). For mucoid PA or failed eradication, ciprofloxacin (3 weeks) and extended nebulized therapy (3 months, alternating tobramycin/colistin) were used. Intravenous antibiotics were given to unwell patients.</p><p><strong>Results: </strong>Among 109 CF patients (median age: 6 years), 79 (72.5%) achieved successful eradication. Oral ciprofloxacin and tobramycin inhalation were used in 66 patients (60.6%), extended nebulized therapy in 26 (23.8%), and intravenous antibiotics in 17(15.6%).</p><p><strong>Conclusion: </strong>The revised protocol achieved a high PA eradication rate in CF patients. Adapting treatment regimens based on PA characteristics and patient condition can optimize outcomes and improve CF management.</p>\",\"PeriodicalId\":10363,\"journal\":{\"name\":\"Clinical Pediatrics\",\"volume\":\" \",\"pages\":\"1581-1588\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pediatrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/00099228251351699\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00099228251351699","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
Effective Pseudomonas aeruginosa Eradication in Cystic Fibrosis: Multicenter Study.
Background: Pseudomonas aeruginosa (PA) eradication is crucial in cystic fibrosis (CF) management. At our center, the success rate was 21.6%, prompting a revised eradication protocol to evaluate a new regimen.
Methods: Cystic fibrosis patients with first-time PA detection were included. Nonmucoid PA cases received oral ciprofloxacin (3 weeks) and inhaled tobramycin (1 month). For mucoid PA or failed eradication, ciprofloxacin (3 weeks) and extended nebulized therapy (3 months, alternating tobramycin/colistin) were used. Intravenous antibiotics were given to unwell patients.
Results: Among 109 CF patients (median age: 6 years), 79 (72.5%) achieved successful eradication. Oral ciprofloxacin and tobramycin inhalation were used in 66 patients (60.6%), extended nebulized therapy in 26 (23.8%), and intravenous antibiotics in 17(15.6%).
Conclusion: The revised protocol achieved a high PA eradication rate in CF patients. Adapting treatment regimens based on PA characteristics and patient condition can optimize outcomes and improve CF management.
期刊介绍：
Clinical Pediatrics (CLP) a peer-reviewed monthly journal, is a must read for the busy pediatrician. CLP contains state-of-the-art, accurate, concise and down-to earth information on practical, everyday child care topics whether they are clinical, scientific, behavioral, educational, or ethical.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
